To estimate the cost-effectiveness of treatment with long-acting methylphenidate-OROS for youths with attention-deficit/hyperactivity disorder (ADHD) for whom treatment with immediate-release (IR) methylphenidate is suboptimal.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is the most common mental health disorder in youths. ADHD is a chronic disorder and for the majority of youths symptoms persist into adolescence and adulthood. ADHD is linked to academic failure, poor self-esteem, troublesome peer and family relationships [1] [2] [3] [4] .
In general, medication is the most effective therapy for patients with ADHD [2, 5] . In the largest clinical trial on the treatment of ADHD performed so far, the 14-month Multimodal Treatment Study of Children with ADHD, medication management proved more effective compared to behavioral therapy and community care [5] Stimulants are the drugs of first choice, as they have been shown to improve ADHD symptoms in approximately 70-80% of youths with ADHD [6] . The most commonly prescribed stimulant is methylphenidate.
Methylphenidate has a half-life of 2-4 hours, which demands frequent dosing in order to achieve symptom control throughout the day. Consequently, there is a chance of suboptimal symptom control if the timing of medication intake is inappropriate, i.e. not within 3-4 hours of the previous dose. The short duration of action of methylphenidate therefore necessitates frequent and accurate intake of medication, also during school hours. This may lead to practical difficulties if the school staff is not willing or able to take responsibility for the administration of medication. For older children, the intake of medication during school hours may involve embarrassment and social stigma [7] . To overcome these difficulties, longeracting formulations with methylphenidate were developed and introduced.
In the Netherlands, only immediate-release preparations with methylphenidate (IRmethylphenidate) were available, until the registration of methylphenidate-OROS in November 2002. Methylphenidate-OROS is an osmotic controlled-release delivery formulation with methylphenidate designed for once-daily oral dosing. In clinical trials methylphenidate-OROS once daily has been shown to be as effective as IRmethylphenidate 3 times a day with a similar safety pattern, under tightly controlled conditions such as laboratory schools or clinical trials [8] . Recent studies suggest that methylphenidate-OROS has beneficial effects on treatment adherence [9, 10] .
Several publications have shown that ADHD places a substantial economic burden on patients, families and society [11] [12] [13] [14] . If long-term consequences of untreated or suboptimally treated ADHD could be prevented with effective treatment, the total cost to society might decrease. In this respect, it has been suggested that it is likely that the full costs associated with the treatment of ADHD (i.e. not only drug costs) may be reduced by once-daily dosing regimens [15] In this study we aim to investigate this latter aspect by estimating the cost-effectiveness of treatment with methylphenidate-OROS for youths with ADHD for whom treatment with IR-methylphenidate is suboptimal.
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Methods
General Model Outline
We developed a Markov model, preceded by a primary phase, comparing costs, financial benefits, health gains and utilities of treatment with methylphenidate-OROS to IRmethylphenidate. We applied this model to the specific patient group of youths with an ADHD diagnosis who are responders to IR-methylphenidate treatment, but for whom current IR-methylphenidate treatment is suboptimal due to insufficient exposure to this medication over the day caused by problems with the multiple daily dosing. As ADHD is a chronic disorder, we calculated costs and utilities over a period of 10 years, assuming youths start treatment with IR-methylphenidate at the age of 8. As there may be non-compliance on a daily basis, a Markov cycle of one day was chosen.
We performed a cost-effectiveness analysis from a societal/community perspective as far as data availability allowed us to. The outcome of the model is the incremental costeffectiveness ratio (ICER) reported in net costs per quality-adjusted life year (QALY). QALYs were based on a study assessing health state utilities for ADHD in the United Kingdom (see below for details) [16] . Total costs include medication, consultations and treatment interventions and additional costs for attending special education in the Netherlands. The resource use (i.e. consultations, interventions and special education) underlying the costs was based on expert panel opinions. We organized an expert panel with 3 pediatricians and 2 child psychiatrists with expertise in diagnosing and treating youths with ADHD from different regions in the Netherlands. We inquired the experts about the proportions of nonresponders, bad responders (adverse effects) and responders to treatment with IRmethylphenidate, and about the mean dose of methylphenidate. Furthermore, the experts estimated the frequency of consultations and non-pharmacological interventions among youths diagnosed with ADHD for whom treatment with methylphenidate leads to full or partial control of ADHD symptoms (optimal response and/or suboptimal response) or who had stopped treatment with methylphenidate despite ADHD symptoms. We also asked them to provide an estimation of the percentage of these youths attending special education. The same questions were posed for youths aged 12 years or younger and for youths older than 12 years. From the estimations provided by the experts we calculated a weighted average, taking into account the ratio between stimulant-treated youths being treated by pediatricians and child psychiatrists in the Netherlands (34:46) (Table 2 and 3) [17] .
Model Details
Our expert panel estimated that of all youths with ADHD starting with IR-methylphenidate treatment, 47% shows optimal symptom control, 42% shows suboptimal symptom control, 91 and 11% experiences serious adverse reactions (for a description of the composition and data generating for this panel see below). For the latter group methylphenidate is not an effective treatment option, and these youths will switch to other treatments, such as nonstimulants or non-pharmacological treatments. The 42% with suboptimal symptom control enter our model in the primary phase receiving either IR-methylphenidate or methylphenidate-OROS (Figure 1 ). For the 42% youths entering our model, treatment may be not optimally effective due to non-response or inappropriate (or no) intake of IRmethylphenidate. The weighted estimates of the expert panel members were 17% for nonresponse and 83% for inappropriate (or no) intake. Non-response rates were assumed the same for IR-methylphenidate and OROS-methylphenidate. For non-responders (17%) treatment with either IR-methylphenidate or methylphenidate-OROS is stopped after the 2-month primary phase, as treatment turns out to be ineffective (note that medication costs during this primary phase are recorded in the model). The 83% responders enter the Markov phase. For these youths, we compared costs and quality of life of (sub)optimal response with IR-methylphenidate to optimal response with methylphenidate-OROS. Therefore we 
Transition probabilities
The transition probabilities used in our model are presented in table 1. Our expert panel estimated 19.3% of the youths in the suboptimal response state to be able to transfer to the optimal response state on IR-methylphenidate in the first year of treatment or 0.053% per day. We assumed this probability to decline linearly to 0% after 10 years' follow-up.
The probability of youths using methylphenidate-OROS to be non-compliant for one day was derived from the randomized, controlled trial described by Steele et al [9] . At the endpoint of the 8-week trial 56% of the subjects in the methylphenidate-OROS group missed at least one dose during the trial, with a mean total number of missed doses of 1. on these figures we derived a probability of non-compliance for youths using methylphenidate-OROS of 0.019 per day, assuming this probability to be constant over time.
Duration of stimulant use was estimated using pharmacy dispensing data from the Inter Action Database (IADB). The IADB covers all prescriptions from an estimated population of approximately 450,000 people in the northern and eastern part of the Netherlands since 1999. This database includes all prescriptions, regardless of prescriber, insurance, or reimbursement status, apart from over-the-counter drugs and drugs dispensed during a hospital stay [18, 19] . Due to a high patient-pharmacy commitment in the Netherlands and sophisticated pharmacy software, the medication records for each patient are virtually complete [20] . Duration of stimulant use was estimated for all incident users in 2000-2002 aged 5-9 years (n = 260, 95% used methylphenidate, 5% dexamphetamine), using Kaplan
Meier survival estimators. To focus on responders to methylphenidate treatment youths exposed for 60 days or less were excluded. Stimulant treatment was considered stopped when a child had not received prescribed stimulants within the 180 following the end date of the final prescription. Based on the Kaplan Meier survival estimates, we derived a discontinuation hazard of 0.0003 per day for the first 180 days of stimulant use, followed by a hazard of 0.0002. The probability of stopping treatment was the same for IRmethylphenidate and methylphenidate-OROS in the base case analysis.
The probability of functional remission of ADHD per day was derived from Biederman's study among ADHD youths aged 6-8 to 18-20 years [21] . In this study functional remission was defined as the loss of partial diagnostic status plus functional recovery (full recovery).
The prevalence of functional remission was 10% in the oldest age group of 18-20 years. For our model we assumed a 10% functional remission over 12 years, which implies a probability of 0.00002 per day. We assumed the probability of functional remission to be constant over time and to be the same for IR-methylphenidate and methylphenidate-OROS in the base case analysis.
Costs
For the total costs in the methylphenidate-OROS and IR-methylphenidate pathways we included medication and resource use, i.e. consultations and interventions and additional costs for attending special education (Table 4) .
From the expert panel the mean dose of IR-methylphenidate at the age of 8 years was estimated at 21.4mg, and 49.6 mg at the age of 18 years. We assumed a linear increase of the mean dose over the 10 year follow-up period. The mean dose of methylphenidate-OROS was calculated by increasing the IR-methylphenidate dose by 20%, as stated in the registration file.
Functional remission of ADHD 0.00002 (5) 0.00002 (5) 0.00002 (5) 1 0.00002 (5) 0.00002 (5) 0.00002 (5) 1 Treatment stopped 0.00030 (4) 0.00030 (4) 0.99998 (1) 0 0.00030 (4) 0 0.99998 (1) 0 Non-compliance n.a. n.a. n.a. n.a 0.01900 (3) 0.01900 For youths in the optimal response state a pharmacy fee of 6.10 euros per 3 months was included in the medication costs [22] . We assumed that youths in the suboptimal response state have their stimulant prescription dispensed every 4 months, resulting in a pharmacy fee of 6.10 euros per 4 months. We assumed that no medication costs were incurred in the non-compliance, treatment stopped and functional remission of ADHD states. For the 17% non-responders for whom treatment turned out to be ineffective in the primary phase, medication costs for IR-methylphenidate and methylphenidate-OROS were included in the analysis.
We assumed that costs on non-pharmacological interventions were incurred in the 1st and 6th year of treatment, when the child is aged 8 respectively 13 (after switch from primary to secondary school). Because being non-compliant for day probably does not immediately lead to an increase of resource use (i.e. consultations, interventions and special education), in the base case analysis we assumed for youths in the non-compliance state the same costs as for youths in the optimal response state. For youths in the functional remission of ADHD state, no costs were incurred. Future costs were discounted at the recommended rate of 4% per year [23] .
QALYs
Health state utilities for youths with ADHD were based on a study from the United Kingdom, using parents of youths with ADHD as a proxy. QALYs were assessed using the standard gamble method among 83 parents [16] . We applied QALYs from the following ADHD health states to our model: responder on IR-stimulant without side effects (0.913), responder on extended-release stimulant without side-effects (0.930) and non-responder on no medication (0.899). We assumed the QALY for youths in the suboptimal health state (on IRmethylphenidate) to be between the QALYs for responder on IR-stimulant (0.913) and non-96 responder on IR-stimulant (0.889), i.e. 0.901. Figure 1 shows the Markov states and the corresponding QALYs. Future QALYs were discounted at a rate of 4% per year. 
Sensitivity analysis
To take account of the impact of the different model parameters about which we were most uncertain, we first performed a series of univariate sensitivity analyses. In addition, a worst case incremental cost-effectiveness ratio (ICER, most favorable to IR-methylphenidate pathway) was derived combining all variations that led to an increase of the base case ICER. Analogously, a best case ICER (most favorable to methylphenidate-OROS pathway)
was derived by combining all variations that led to a decrease of the base case ICER.
Results
Base case cost-effectiveness
The ICER of starting methylphenidate-OROS treatment in youths with ADHD for whom treatment with IR-methylphenidate is suboptimal was € 2,004 per QALY (Table 5) . Total costs were € 15,739 for the IR-methylphenidate pathway and € 16,015 for the methylphenidate-OROS pathway. Medication costs for methylphenidate-OROS were six times higher compared to IR-methylphenidate. Costs for consultations, interventions and for attending special education were lower in the methylphenidate-OROS pathway compared to treatment with IR-methylphenidate. Total QALYs were almost similar for both pathways. 
Sensitivity analysis
The univariate sensitivity analysis showed that our model was most sensitive to variations in the resource use in the optimal and suboptimal response state and to varying the probability of stopping IR-methylphenidate treatment versus methylphenidate-OROS treatment ( Figure   2 ). Decreasing the resource use of youths in the suboptimal response state with 25%
resulted in an ICER of € 12,534 per QALY, a 526% increase compared to the base case ICER. Increasing the resource use of youths in the suboptimal response state by 25% resulted in OROS-methylphenidate being dominant, i.e. cheaper and more effective.
Increasing the probability of stopping treatment only for the IR-methylphenidate pathway by 25% raised the ICER to € 11,885 per QALY.
Discounting QALYs at 1.5% reduced the ICER to € 1,845 per QALY. Increasing the price of methylphenidate-OROS by 25% raised the ICER to € 10,054 per QALY. In our model, an ICER of 0 was reached with a 6.2% price reduction of methylphenidate-OROS. The worst case ICER was estimated at € 38,363 per QALY. The best case multivariate analysis (most favorable to methylphenidate-OROS) resulted in a situation of dominance again, due to cost savings in the methylphenidate-OROS pathway.
Discussion
Our cost-effectiveness analysis showed that for youths with ADHD for whom treatment with IR-methylphenidate is suboptimal, the 10-year costs of methylphenidate-OROS and IRmethylphenidate are comparable. The incremental cost-effectiveness ratio of methylphenidate-OROS in these youths was calculated to be € 2,004 per QALY, which is amply below generally applied threshold values of € 20,000 to € 30,000, and therefore may be considered a cost-effective treatment. The calculated ratio was sensitive to changes in resource use and the probability of stopping stimulant treatment in favor of IR-0  2000  4000  6000  8000  10000  12000  14000  16000 Baseline analysis
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Costs OROS-methylphenidate -25% estimates were subjected to sensitivity analyses, which showed our result to be rather stable. Another limitation of our model is that youths who stopped treatment could not start treatment again during the 10 years follow-up. Furthermore, the probability of being noncompliant on methylphenidate-OROS was derived from an 8-week randomized, controlled, open-label study [9] . An 8-week compliance rate presumably does not reflect daily compliance over 10 years' follow-up, and therefore we may have underestimated noncompliance. Univariate sensitivity analysis, however, showed the ICER to be insensitive for changes in compliance rates. Two recent publications reported that youths treated with methylphenidate-OROS were less likely to discontinue treatment compared to IRmethylphenidate users [24, 25] . In our model, however, the discontinuation rate for users of IR-methylphenidate and methylphenidate-OROS was assumed to be the same, which implies that we favored the IR-methylphenidate pathway in our calculations. Taking these limitations into account, we think our analysis may still be seen as conservative towards methylphenidate-OROS.
Lage et al. showed patients on methylphenidate-OROS to be less likely to experience an accident or injury [24] , which could imply cost savings in favor of methylphenidate-OROS that were not included in our model. In addition, in our model no account was taken of direct non-medical costs associated with e.g. in-school administration of IR-methylphenidate. Also, no full picture on indirect costs could be provided, due to for example a lack of data on parental work loss. A cost analysis from the USA showed the impact of including nonmedical costs: in this study IR-methylphenidate treatment appeared to cost US$449 more per year than methylphenidate-OROS, a cost difference fully attributable to in-school administration costs [15] . Vanoverbeke et al built an economic model for the United Kingdom, comparing 1-year costs of treatment with IR-methylphenidate and methylphenidate-OROS [26] . Annual total costs in this study were comparable, i.e. £1,362
for IR-methylphenidate and £1,332 for methylphenidate-OROS. A cost-effectiveness analysis was not included in this paper, but given the marginal difference in costs, they expected the cost-effectiveness of methylphenidate-OROS to be superior to that of IRmethylphenidate, as they assumed the effectiveness of methylphenidate-OROS (77.8%) to be better than that of IR-methylphenidate (55.6%).
Cost-effectiveness is an increasingly important topic for new drugs and many countries nowadays require pharmaco-economic studies for reimbursement decisions [27] . Our analysis underlines the necessity to focus on the total treatment costs, and not only on the costs of the drug itself. In the particular case studied here the drug costs associated with methylphenidate-OROS are almost six times higher than those associated with IRmethylphenidate, which of course raised the question on its cost-effectiveness. However, we
showed that for ADHD children for whom IR-methylphenidate treatment is suboptimal, these higher drug costs are compensated for by savings on other cost items, which in the end resulted in a cost-effectiveness ratio in favor of methylphenidate-OROS. According to our model, a 6.2% reduction of the methylphenidate-OROS price could make the methylphenidate-OROS pathway cost-saving.
Future research should attempt to retrieve estimations for model parameters from clinical trials or large databases, in order to further investigate the full societal impact of ADHD and its treatment. In addition, direct non-medical costs associated with methylphenidate treatment should be investigated and included in future cost-effectiveness analysis.
